Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Amicus Therapeutics's share price for the quarter that ended in Dec. 2023 was $14.19. Amicus Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 293.6 Mil. Therefore, Amicus Therapeutics's market cap for the quarter that ended in Dec. 2023 was $4,166.1 Mil.
Amicus Therapeutics's quarterly market cap
declined
from Jun. 2023 ($3,604.6 Mil) to Sep. 2023 ($3,534.5 Mil) but then
increased
from Sep. 2023 ($3,534.5 Mil) to Dec. 2023 ($4,166.1 Mil).
Amicus Therapeutics's annual market cap
increased
from Dec. 2021 ($3,221.4 Mil) to Dec. 2022 ($3,432.3 Mil) and
increased
from Dec. 2022 ($3,432.3 Mil) to Dec. 2023 ($4,166.1 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Amicus Therapeutics's Enterprise Value for Today is $3,171.0 Mil.
Amicus Therapeutics Market Cap Historical Data
The historical data trend for Amicus Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Amicus Therapeutics's Market Cap
For the Biotechnology subindustry, Amicus Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amicus Therapeutics's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Amicus Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Amicus Therapeutics's Market Cap falls into.
Amicus Therapeutics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Amicus Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amicus Therapeutics (NAS:FOLD) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Amicus Therapeutics Market Cap Related Terms
Thank you for viewing the detailed overview of Amicus Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Amicus Therapeutics (Amicus Therapeutics) Business Description
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FOLD has been successfully added to your 